Skip to content
Research Article Open access CC BY 4.0

The Synergy of Molecular Docking and Bioinformatics: An in Depth Review in Drug Discovery

Okpo, E. A., Agboke, A. A., Udobi, C. E., John, G. E., Andy, I. E.

Biotechnology Journal International · pp. 119–136 · Published 25 Jul 2024

10.9734/bji/2024/v28i4732

Abstract

Molecular docking and bioinformatics have emerged as pivotal tools in the realm of drug discovery, significantly transforming the landscape of pharmaceutical research and development. These computational techniques enable scientists to predict, analyze, and expedite the identification of potential drug candidates with remarkable precision and efficiency. Molecular docking facilitates the virtual screening of vast compound libraries, offering a cost-effective means of selecting promising lead compounds for further study. Bioinformatics, on the other hand, harnesses the power of biological data analysis, encompassing genomics, proteomics, and other omics fields to elucidate disease mechanisms, identify drug targets, and advance personalized medicine. Recent innovations, including the integration of artificial intelligence, cryo-electron microscopy, and quantum computing, are poised to propel these tools further into the future of drug discovery. However, alongside these advancements, ethical and regulatory considerations regarding data privacy, algorithmic fairness, transparency, and adherence to legal and ethical guidelines must be carefully navigated. Striking a harmonious balance between innovation and ethical practice is paramount as molecular docking and bioinformatics continue to reshape the landscape of healthcare and pharmaceutical research.

Molecular docking bioinformatics drugs discovery bioavailability

References (46)

  1. 1 Gene Ontology: tool for the unification of biology [DOI]
  2. 2 AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading [DOI]
  3. 3 KEGG: Kyoto Encyclopedia of Genes and Genomes [DOI]
  4. 4 AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility [DOI]
  5. 5 New Algorithms and Methods to Estimate Maximum-Likelihood Phylogenies: Assessing the Performance of PhyML 3.0 [DOI]
  6. 6 STRING v11: protein–protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets [DOI]
  7. 7 Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings 1PII of original article: S0169-409X(96)00423-1. The article was originally published in Advanced Drug Delivery Reviews 23 (1997) 3–25. 1 [DOI]
  8. 8 SWISS-MODEL: homology modelling of protein structures and complexes [DOI]
  9. 9 Basic Local Alignment Search Tool [DOI]
  10. 10 A framework for variation discovery and genotyping using next-generation DNA sequencing data [DOI]
  11. 11 Open Babel: An open chemical toolbox [DOI]
  12. 12 The Phyre2 web portal for protein modeling, prediction and analysis [DOI]
  13. 13 CHARMM36m: an improved force field for folded and intrinsically disordered proteins [DOI]
  14. 14 An approach to correlate tandem mass spectral data of peptides with amino acid sequences in a protein database [DOI]
  15. 15 Network pharmacology: the next paradigm in drug discovery [DOI]
  16. 16 A point‐charge force field for molecular mechanics simulations of proteins based on condensed‐phase quantum mechanical calculations [DOI]
  17. 17 Docking and scoring in virtual screening for drug discovery: methods and applications [DOI]
  18. 18 Can the pharmaceutical industry reduce attrition rates? [DOI]
  19. 19 How to improve R&D productivity: the pharmaceutical industry's grand challenge [DOI]
  20. 20 Drug Discovery: A Historical Perspective [DOI]
  21. 21 I-TASSER server: new development for protein structure and function predictions [DOI]
  22. 22 The influence of drug-like concepts on decision-making in medicinal chemistry [DOI]
  23. 23 Computational Methods in Drug Discovery [DOI]
  24. 24 Pharmacogenomics Knowledge for Personalized Medicine [DOI]
  25. 25 How were new medicines discovered? [DOI]
  26. 26 UniProt Knowledgebase: a hub of integrated protein data [DOI]
  27. 27 Emerging landscape of oncogenic signatures across human cancers [DOI]
  28. 28 Accurate and Reliable Prediction of Relative Ligand Binding Potency in Prospective Drug Discovery by Way of a Modern Free-Energy Calculation Protocol and Force Field [DOI]
  29. 29 Molecular dynamics simulations and drug discovery [DOI]
  30. 30 A reference map of the human binary protein interactome [DOI]
  31. 31 Integrative omics for health and disease [DOI]
  32. 32 Machine learning in chemoinformatics and drug discovery [DOI]
  33. 33 Computer-based de novo design of drug-like molecules [DOI]
  34. 34 Discovering the anticancer potential of non-oncology drugs by systematic viability profiling [DOI]
  35. 35 The BioMart community portal: an innovative alternative to large, centralized data repositories [DOI]
  36. 36 Native protein sequences are close to optimal for their structures [DOI]
  37. 37 Toward interoperable bioscience data [DOI]
  38. 38 Performance of machine-learning scoring functions in structure-based virtual screening [DOI]
  39. 39 Deciphering Protein–Protein Interactions. Part II. Computational Methods to Predict Protein and Domain Interaction Partners [DOI]
  40. 40 How (not) to protect genomic data privacy in a distributed network: using trail re-identification to evaluate and design anonymity protection systems [DOI]
  41. 41 De Novo Design at the Edge of Chaos [DOI]
  42. 42 Discovery of a Bioactive Inhibitor with a New Scaffold for Cystathionine γ-Lyase [DOI]
  43. 43 Cytoscape: A Software Environment for Integrated Models of Biomolecular Interaction Networks [DOI]
  44. 44 Network target for screening synergistic drug combinations with application to traditional Chinese medicine [DOI]
  45. 45 Opportunities and obstacles for deep learning in biology and medicine [DOI]
  46. 46 A Network Integration Approach for Drug-Target Interaction Prediction and Computational Drug Repositioning from Heterogeneous Information [DOI]

Cited by 21

A review of the current trends in computational approaches in drug design and metabolism

Russell B. O. Ouma, Silas M. Ngari, Joshua K. Kibet · Discover Public Health · 2024

Molecular Docking and Antihypertensive Activity of Eupalitin 3-O-β-D-galactopyranoside Isolated from Boerhavia diffusa Linn

Ilyas Uoorakkottil, Rashid Koottangodan, Kamal Y. Thajudheen · Pharmaceutics · 2024

Advances in the Design of Novel Antidiabetic Agents Using In-silico Approaches

Sanket Jadhav, Pranali Yeram, Rajasekhar Reddy Alavala · Applications of Computational Tools in Drug Design and Development · 2025

Showing 9 of 21 known citations — external sources report more than can currently be individually listed.

Article metrics

Real usage data collected on this platform.

25

Page views

0

PDF downloads

4

Outbound clicks

21

Citations

Views over time

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

Traffic sources

Referring site, by host.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.